Suekane Shigetaka 末金茂高

… Alternative Names

末金茂高スエカネシゲタカ

Less

Researcher Number	40235833
Other IDs
Affiliation (Current)	2025: 久留米大学, 医学部, 准教授
Affiliation (based on the past Project Information) *help	2015 – 2021: 久留米大学, 医学部, 准教授 2004 – 2005: 久留米大学, 医学部, 助手 1998 – 1999: 久留米大学, 医学部, 助手
Review Section/Research Field	Principal Investigator Urology / Basic Section 56030:Urology-related / Urology
Keywords	Principal Investigator 尿路上皮がん / がんペプチドワクチン / 個別化治療 / 尿路がん / がんワクチン / 複合療法 / 複合免疫療法 / がん免疫療法 / 生存率 / サイトカイン … More / バイオマーカー / ペプチドワクチン / 癌ペプチドワクチン / 腎細胞癌 / 細胞傷害性Tリンパ球 / HLA拘束性 / 免疫療法 / エスケープ現象 / 特異免疫 / HLA-A2 / 遺伝子クローニング / 癌拒絶抗原 / キラーT細胞 / 精巣腫瘍 Less

Next generation personalized peptide vaccination for advanced urothelial carcinoma patientsPrincipal Investigator
- Principal Investigator
  
  Suekane Shigetaka
- Project Period (FY)
  2018 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56030:Urology-related
- Research Institution
  Kurume University
Biomarkers of personalized peptide vaccination for metastatic upper tract urothelial carcinomaPrincipal Investigator
- Principal Investigator
  
  Suekane Shigetaka
- Project Period (FY)
  2015 – 2017
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Kurume University
腎癌ワクチン開発の基礎および臨床研究Principal Investigator
- Principal Investigator
  
  末金茂高
- Project Period (FY)
  2004 – 2005
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Urology
- Research Institution
  Kurume University
精巣腫瘍浸潤キラーT細胞の解析と癌拒絶抗原遺伝子のクローニングPrincipal Investigator
- Principal Investigator
  
  末金茂高
- Project Period (FY)
  1998 – 1999
- Research Category
  
  Grant-in-Aid for Encouragement of Young Scientists (A)
- Research Field
  
  Urology
- Research Institution
  Kurume University

All 2022 2021 2020 2019 2018 2017 2016

All Journal Article Presentation

[Journal Article] Impact of Gleason score of the tumor at the positive surgical margin as a prognostic factor2022
- Author(s)
  Kurose Hirofumi、Ueda Kosuke、Ogasawara Naoyuki、Chikui Katsuaki、Nakiri Makoto、Nishihara Kiyoaki、Matsuo Mitsunori、Suekane Shigetaka、Kusano Hironori、Akiba Jun、Yano Hirohisa、Igawa Tsukasa
- Journal Title
  
  Molecular and Clinical Oncology
  
  Volume: 16 Issue: 4 Pages: 1-7
- DOI
  10.3892/mco.2022.2515
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09182
[Journal Article] Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching2022
- Author(s)
  Nishiyama Naotaka、Kobayashi Takashi、Suekane Shigetaka、Nagasawa Seiji、Higashi Shin、Fukui Tomohiro、Kojima Takahiro、Morita Satoshi、Ogawa Osamu、Nishiyama Hiroyuki、Kitamura Hiroshi
- Journal Title
  
  Journal of Geriatric Oncology
  
  Volume: 13 Issue: 1 Pages: 88-93
- DOI
  10.1016/j.jgo.2021.07.002
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-18K09182
[Journal Article] Survival outcomes of non?definitive therapy for muscle?invasive bladder cancer2022
- Author(s)
  Nishihara Kiyoaki、Ueda Kosuke、Kurose Hirofumi、Ogasawara Naoyuki、Hiroshige Tasuku、Chikui Katsuaki、Ejima Kazuhisa、Uemura Keiichiro、Nakiri Makoto、Suekane Shigetaka、Igawa Tsukasa
- Journal Title
  
  Oncology Letters
  
  Volume: 23 Issue: 4 Pages: 1-8
- DOI
  10.3892/ol.2022.13246
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09182
[Journal Article] Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab2022
- Author(s)
  Ueda Kosuke、Suekane Shigetaka、Kurose Hirofumi、Ito Naoki、Ogasawara Naoyuki、Hiroshige Tasuku、Chikui Katsuaki、Ejima Kazuhisa、Uemura Keiichiro、Nakiri Makoto、Nishihara Kiyoaki、Igawa Tsukasa
- Journal Title
  
  Japanese Journal of Clinical Oncology
  
  Volume: 1 Issue: 5 Pages: 1-8
- DOI
  10.1093/jjco/hyac009
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09182, KAKENHI-PROJECT-20K18128
[Journal Article] Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab2021
- Author(s)
  Ueda Kosuke、Suekane Shigetaka、Kurose Hirofumi、Ogasawara Naoyuki、Hiroshige Tasuku、Chikui Katsuaki、Uemura Keiichiro、Nakiri Makoto、Nishihara Kiyoaki、Matsuo Mitsunori、Igawa Tsukasa
- Journal Title
  
  Japanese Journal of Clinical Oncology
  
  Volume: 52 Issue: 2 Pages: 179-186
- DOI
  10.1093/jjco/hyab157
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09182, KAKENHI-PROJECT-20K18128
[Journal Article] Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR2021
- Author(s)
  Kobayashi Takashi、Ito Katsuhiro、Suekane Shigetaka、Nagasawa Seiji、Higashi Shin、Fukui Tomohiro、Ogawa Osamu、Kitamura Hiroshi、Nishiyama Hiroyuki
- Journal Title
  
  Cancer Immunology, Immunotherapy
  
  Volume: 71 Issue: 2 Pages: 461-471
- DOI
  10.1007/s00262-021-03000-8
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09182
[Journal Article] Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide‐based vaccine2020
- Author(s)
  Kurahashi Ryoma、Motoshima Takanobu、Fukushima Yumi、Murakami Yoji、Yatsuda Junji、Yamaguchi Takahiro、Sugiyama Yutaka、Fukushima Satoshi、Komohara Yoshihiro、Suekane Shigetaka、Kamba Tomomi
- Journal Title
  
  IJU Case Reports
  
  Volume: 3 Issue: 2 Pages: 44-48
- DOI
  10.1002/iju5.12139
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K09182, KAKENHI-PROJECT-20K09560
[Journal Article] Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients2020
- Author(s)
  Suekane Shigetaka、Yutani Shigeru、Yamada Akira、Sasada Tetsuro、Matsueda Satoko、Takamori Shinzo、Toh Uhi、Kawano Kouichiro、Yoshiyama Koichi、Sakamoto Shinjiro、Sugawara Shunichi、Komatsu Nobukazu、Yamada Teppei、Naito Masayasu、Terasaki Mizuhiko、Mine Takashi、Itoh Kyogo、Shichijo Shigeki、Noguchi Masanori
- Journal Title
  
  International Journal of Oncology
  
  Volume: 56 Pages: 1479-1489
- DOI
  10.3892/ijo.2020.5019
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09182, KAKENHI-PROJECT-17H04278, KAKENHI-PROJECT-18K19490
[Journal Article] Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial2020
- Author(s)
  Noguchi Masanori、Arai Gaku、Egawa Shin、Ohyama Chikara、Naito Seiji、Matsumoto Kazumasa、Uemura Hirotsugu、Nakagawa Masayuki、Nasu Yasutomo、Eto Masatoshi、Suekane Shigetaka、Sasada Tetsuro、Shichijo Shigeki、Yamada Akira、Kakuma Tatsuyuki、Itoh Kyogo
- Journal Title
  
  Cancer Immunology, Immunotherapy
  
  Volume: 69 Issue: 5 Pages: 847-857
- DOI
  10.1007/s00262-020-02498-8
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09182, KAKENHI-PROJECT-17H04278, KAKENHI-PROJECT-18K19490
[Journal Article] The Impact of Antibiotics on Prognosis of Metastatic Renal Cell Carcinoma in Japanese Patients Treated With Immune Checkpoint Inhibitors2019
- Author(s)
  UEDA KOSUKE、YONEKURA SATORU、OGASAWARA NAOYUKI、MATSUNAGA YOSHIHIRO、HOSHINO RYUJI、KUROSE HIROFUMI、CHIKUI KATSUAKI、UEMURA KEIICHIRO、NAKIRI MAKOTO、NISHIHARA KIYOAKI、MATSUO MITSUNORI、SUEKANE SHIGETAKA、IGAWA TSUKASA
- Journal Title
  
  Anticancer Research
  
  Volume: 39 Issue: 11 Pages: 6265-6271
- DOI
  10.21873/anticanres.13836
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K09182
[Journal Article] Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers2018
- Author(s)
  Masanori Noguchi, Noriko Koga, Fukuko Moriya, Shigetaka Suekane, Shigeru Yutani, Akira Yamada, Shigeki Shichijo, Tatuyuki Kakuma, Kyogo Itoh
- Journal Title
  
  Cancer Science
  
  Volume: 109 Issue: 9 Pages: 2660-2669
- DOI
  10.1111/cas.13709
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K09182
[Journal Article] Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.2017
- Author(s)
  Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M.
- Journal Title
  
  Cancer Sci.
  
  Volume: 108 Issue: 12 Pages: 2430-2437
- DOI
  10.1111/cas.13404
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17H04278, KAKENHI-PROJECT-15K10614, KAKENHI-PROJECT-16K15601
[Presentation] Phase I/II study to evaluate the efficacy of TAS0313, the cancer peptide vaccine, in combination with pembrolizumab in locally advanced or metastatic urothelial carcinoma.2021
- Author(s)
  Ryuji Matsumoto, Junji Yonese, Takahiro Kojima, Hideaki Miyake, Nobuaki Matsubara, Hiroji Uemura, Masatoshi Eto, Naokazu Ibuki, Wataru Obara, Akito Terai, Satoshi Fukasawa, Shigetaka Suekane, Hiroyuki Nishiyama
- Organizer
  ASCO Annual Meeting
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] 尿路上皮がん患者に対する個別化がんぺプチドワクチン療法のバイオマーカー2020
- Author(s)
  末金茂高、西原聖顕、植田浩介、由谷茂、七條茂樹、野口正典、伊東恭悟、井川掌
- Organizer
  第108回日本泌尿器科学会総会
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine2019
- Author(s)
  S.Suekane, M.Noguchi, M.Terasaki, S.Yutani, Y.Narita, A.Yamada, S.Shichijo, T.Igawa,
- Organizer
  ESMO Congress 2019
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] Feasibility of Personalized Peptide Vaccination for Urothelial Cancer Patients Without Distant Metastasis as a Preventive Cancer Vaccine2019
- Author(s)
  Suekane S,Ueda K,Nishihara K,Noguchi M,Yutani S,Shichijo S,Itoh K,Igawa T
- Organizer
  SIU　2019国際泌尿器科学会議
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] 尿路上皮がん患者に対する個別化がんペプチドワクチンの再発予防効果2019
- Author(s)
  末金　茂高、植田　浩介、西原　聖顕、野口　正典、伊東　恭悟、井川　掌
- Organizer
  第107回日本泌尿器科学会総会
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] 尿路上皮がん再発予防がんペプチドワクチンの免疫誘導能2019
- Author(s)
  末金　茂高、野口　正典、西原　聖顕、植田　浩介、由谷　茂、伊東　恭悟、井川　掌
- Organizer
  第40回癌免疫外科研究会
- Invited
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] 尿路上皮がんに対するがんペプチドワクチン療法2018
- Author(s)
  末金茂高
- Organizer
  第70回西日本泌尿器科学会総会
- Invited
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] 尿路上皮がん患者に対する次世代個別化がんペプチドワクチン療法開発の展望2018
- Author(s)
  末金茂高
- Organizer
  第106回日本泌尿器科学会総会
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] 尿路上皮がん患者に対する個別化がんペプチドワクチン療法の予防効果の検証2018
- Author(s)
  末金茂高
- Organizer
  第56回日本癌治療学会総会
- Data Source
  KAKENHI-PROJECT-18K09182
[Presentation] 転移性上部尿路上皮がん患者に対するがんペプチドワクチン療法のバイオマーカー探索2017
- Author(s)
  末金茂高
- Organizer
  第105回日本泌尿器科学会総会
- Data Source
  KAKENHI-PROJECT-15K10614
[Presentation] 転移性上部尿路上皮がん患者に対するぺプチド特異CTL誘導のバイオマーカー2017
- Author(s)
  末金茂高
- Organizer
  第55回日本癌治療学会総会
- Data Source
  KAKENHI-PROJECT-15K10614
[Presentation] 転移性上部尿路上皮がん患者に対するペプチド特異CTL誘導のバイオマーカー2017
- Author(s)
  末金茂高
- Organizer
  第55回日本癌治療学会総会
- Place of Presentation
  パシフィコ横浜
- Year and Date
  2017-10-20
- Data Source
  KAKENHI-PROJECT-15K10614
[Presentation] Phase Ⅱ　study of personalized peptide vaccination for metastatic upper urinary tract urothelial cancer patients refractory to the standard chemotherapy2017
- Author(s)
  末金茂高
- Organizer
  AUA2017
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K10614
[Presentation] Phase II study of personalized peptide vaccination for metastatic upper tract urothelial cancer patients refractory to the standard chemotherapy2017
- Author(s)
  末金茂高
- Organizer
  AUA2017
- Place of Presentation
  米国ボストン
- Year and Date
  2017-05-12
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K10614
[Presentation] 個別化がんペプチドワクチン療法2017
- Author(s)
  末金茂高
- Organizer
  第105回日本泌尿器科学会総会
- Invited
- Data Source
  KAKENHI-PROJECT-15K10614
[Presentation] プラチナ系薬治療抵抗性転移性上部尿路上皮がん患者に対するがんペプチドワクチン療法2016
- Author(s)
  末金茂高
- Organizer
  日本癌治療学会
- Place of Presentation
  パシフィコ横浜
- Year and Date
  2016-10-20
- Data Source
  KAKENHI-PROJECT-15K10614
[Presentation] 尿路上皮がん患者に対するがんペプチドワクチン療法の可能性2016
- Author(s)
  末金茂高
- Organizer
  日本泌尿器科学会東部総会
- Place of Presentation
  ホテル青森
- Year and Date
  2016-10-07
- Data Source
  KAKENHI-PROJECT-15K10614

1. MORIYA Fukuko (80449917)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
2. 伊東恭悟 (50125499)

# of Collaborated Projects: 2 results

# of Collaborated Products: 10 results
3. 野口正典 (10140691)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. 井川掌 (40295069)

# of Collaborated Projects: 1 results

# of Collaborated Products: 10 results
5. 植田浩介 (60569440)

# of Collaborated Projects: 1 results

# of Collaborated Products: 10 results
6. 西原聖顕 (90389297)

# of Collaborated Projects: 1 results

# of Collaborated Products: 9 results
7. YAMADA Satoko

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 笹田哲朗

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Suekane Shigetaka 末金 茂高

末金 茂高 スエカネ シゲタカ

Research Projects

Research Products

Co-Researchers

Next generation personalized peptide vaccination for advanced urothelial carcinoma patientsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Biomarkers of personalized peptide vaccination for metastatic upper tract urothelial carcinomaPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

腎癌ワクチン開発の基礎および臨床研究Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

精巣腫瘍浸潤キラーT細胞の解析と癌拒絶抗原遺伝子のクローニングPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Impact of Gleason score of the tumor at the positive surgical margin as a prognostic factor2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Survival outcomes of non?definitive therapy for muscle?invasive bladder cancer2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide‐based vaccine2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The Impact of Antibiotics on Prognosis of Metastatic Renal Cell Carcinoma in Japanese Patients Treated With Immune Checkpoint Inhibitors2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers2018

Suekane Shigetaka 末金茂高

末金茂高スエカネシゲタカ

[Presentation] Phase Ⅱ　study of personalized peptide vaccination for metastatic upper urinary tract urothelial cancer patients refractory to the standard chemotherapy2017